Canaccord analyst Tania Gonsalves lowered the firm’s price target on Antibe Therapeutics to C$0.50 from C$0.70 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly